FDA fast tracks GLP-1 analog for knee osteoarthritis

The FDA has granted fast track designation to 4P004, an intra-articular GLP-1 agonist analog, for the treatment of knee osteoarthritis, according to a press release from biotechnology company 4Moving Biotech.
The agent, which the company is billing as a potential first-in-class disease-modifying osteoarthritis drug, is engineered for intra-articular administration in patients with synovitis who had previously failed on at least two other OA medications.
“The FDA fast track designation granted to 4P004 is an important milestone for 4Moving Biotech and for the osteoarthritis field,” Francis

RNA therapy slows harmful heart remodeling after heart attack in clinical trial

Following an acute heart attack, pathological remodeling processes occur in the heart. One consequence is so-called left ventricular systolic dysfunction, in which the pumping function of the left ventricle is impaired. To compensate for this, the heart muscle enlarges excessively, thereby becoming further weakened. The key regulator of this harmful growth of heart muscle cells is microRNA-132 (miR-132).

Why do heights make your feet feel strange?

I wouldn't say that I'm afraid of heights. I can stand on a cliff path or look out from a tall building without the rush of panic people often associate with vertigo. What I really dislike is something much harder to explain: the peculiar feeling in my feet.